H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 130 KRW 1.92% Market Closed
Market Cap: 192.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note
Hana Pharm Co Ltd
/
Balance Sheet
/
Long-Term Debt

Hana Pharm Co Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hana Pharm Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
H
Hana Pharm Co Ltd
KRX:293480
Long-Term Debt
₩24.9B
CAGR 3-Years
207%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Long-Term Debt
₩127.2B
CAGR 3-Years
34%
CAGR 5-Years
12%
CAGR 10-Years
14%
SK Biopharmaceuticals Co Ltd
KRX:326030
Long-Term Debt
₩121B
CAGR 3-Years
107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Long-Term Debt
₩97.9B
CAGR 3-Years
-31%
CAGR 5-Years
-28%
CAGR 10-Years
-8%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Long-Term Debt
₩36.4B
CAGR 3-Years
8%
CAGR 5-Years
37%
CAGR 10-Years
N/A
C
Celltrion Pharm Inc
KOSDAQ:068760
Long-Term Debt
₩15.6B
CAGR 3-Years
-29%
CAGR 5-Years
-17%
CAGR 10-Years
-19%
No Stocks Found

Hana Pharm Co Ltd
Glance View

Market Cap
192.5B KRW
Industry
Pharmaceuticals

Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Intrinsic Value
18 041.77 KRW
Undervaluation 38%
Intrinsic Value
Price
H
What is Intrinsic Value?

See Also

What is Hana Pharm Co Ltd's Long-Term Debt?
Long-Term Debt
24.9B KRW

Based on the financial report for Sep 30, 2024, Hana Pharm Co Ltd's Long-Term Debt amounts to 24.9B KRW.

What is Hana Pharm Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
63%

Over the last year, the Long-Term Debt growth was 1 235%. The average annual Long-Term Debt growth rates for Hana Pharm Co Ltd have been 207% over the past three years , 63% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.